Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. / Omland, L.H.; Weis, Nina; Skinhoj, P.; Laursen, A.; Christensen, P.B.; Nielsen, H.I.; Moller, A.; Engsig, F.; Sorensen, H.T.; Obel, N.; Omland, L H; Weis, N; Skinhøj, P; Laursen, Al; Christensen, P B; Nielsen, H I; Møller, A; Engsig, F; Sørensen, H T; Obel, N.
I: HIV Medicine, Bind 9, Nr. 5, 2008, s. 300-6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
AU - Omland, L.H.
AU - Weis, Nina
AU - Skinhoj, P.
AU - Laursen, A.
AU - Christensen, P.B.
AU - Nielsen, H.I.
AU - Moller, A.
AU - Engsig, F.
AU - Sorensen, H.T.
AU - Obel, N.
AU - Omland, L H
AU - Weis, N
AU - Skinhøj, P
AU - Laursen, Al
AU - Christensen, P B
AU - Nielsen, H I
AU - Møller, A
AU - Engsig, F
AU - Sørensen, H T
AU - Obel, N
PY - 2008
Y1 - 2008
N2 - BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients Udgivelsesdato: 2008/5
AB - BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients Udgivelsesdato: 2008/5
U2 - 10.1111/j.1468-1293.2008.00564.x
DO - 10.1111/j.1468-1293.2008.00564.x
M3 - Journal article
C2 - 18400077
VL - 9
SP - 300
EP - 306
JO - HIV Medicine
JF - HIV Medicine
SN - 1464-2662
IS - 5
ER -
ID: 10906505